HZNP Stock Recent News

Horizon (HZNP) reports better-than-expected second-quarter results, beating both earnings and sales estimates, with the top-line key contributors being Krystexxa and Uplizna.

The headline numbers for Horizon Therapeutics (HZNP) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Horizon Therapeutics (HZNP) came out with quarterly earnings of $1.20 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $1.07 per share a year ago.

Horizon (HZNP) fails to meet the primary endpoint in the mid-stage study of evaluating daxdilimab in the treatment of systemic lupus erythematosus.

The brisk pace of biopharmaceutical deal making seen in the first half of this year may only accelerate in the months ahead, even as regulators take a hard look at some of the bigger deals, analysts say.

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock?

Last December, Amgen and Horizon agreed to a $27.8 billion buyout agreement. This proposed deal is now in doubt following a report that the FTC plans on challenging the takeover in federal court.

Horizon Therapeutics (NASDAQ: HZNP ) stock is sinking 18% this morning. The Federal Trade Commission (FTC) is reportedly attempting to block the drug maker's proposed merger with Amgen (NASDAQ: AMGN ).

The deal is bid to strengthen Amgen's drug portfolio as it prepares to face several patent expirations for key treatments over the next decade.

Horizon Therapeutics (HZNP) reports lower-than-expected first-quarter 2023 results as it misses the Zacks Consensus Estimates for both revenues and earnings.